Molecular Pharmacology Program
The Richard Kolesnick Lab
Our laboratory focuses on the role of sphingolipid signaling as a stress response. In this pathway, generation of the second messenger ceramide in response to diverse environmental and pharmacologic stresses (heat, ionizing radiation, ultraviolet light, chemotherapeutic agents, oxidative challenges, etc.) occurs either by degradation of sphingomyelin or by de novo synthesis. The quality and quantity of the ceramide response, in combination with other signals, determines whether adaptation or apoptosis ensues. This pathway is evolutionarily conserved and is obligate for the heat shock response in yeast.
Bodo S, Campagne C, Thin TH, Higginson DS, Vargas HA, Hua G, Fuller JD, Ackerstaff E, Russell J, Zhang Z, Klingler S, Cho H, Kaag MG, Mazaheri Y, Rimner A, Manova-Todorova K, Epel B, Zatcky J, Cleary CR, Rao SS, Yamada Y, Zelefsky MJ, Halpern HJ, Koutcher JA, Cordon-Cardo C, Greco C, Haimovitz-Friedman A, Sala E, Powell SN, Kolesnick R, Fuks Z. Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury. J Clin Invest. 2018; pii: 97631.
Martin ML, Zeng Z, Adileh M, Jacobo A, Li C, Vakiani E, Hua G, Zhang L, Haimovitz-Friedman A, Fuks Z, Kolesnick R*, Paty PB*. Logarithmic expansion of LGR5+ cells in human colorectal cancer. Cell Signal. 2018; 42:97-105. doi: 10.1016/j.cellsig.2017.09.018. * Equal co-author.
Van Hell AJ, Haimovitz-Friedman A, Fuks Z, Tap WD, Kolesnick R. Gemcitabine kills proliferating endothelial cells exclusively via acid sphingomyelinase activation. Cell Signal. 2017; 34:86-91. doi: 10.1016/j.cellsig.2017.02.021.
Zhang L, Adileh M, Martin ML, Klingler S, White J, Ma X, Howe LR, Brown AM, Kolesnick R. Establishing estrogen-responsive mouse mammary organoids from single Lgr5+ cells. Cell Signal. 2017; 29:41-51. doi: 10.1016/j.cellsig.2016.08.001.
Richard N. Kolesnick, MD
- Physician-scientist Richard Kolesnick studies the role of ceramide signaling in radiation-induced vascular dysfunction and tumor regression.
- MD, University of Chicago School of Medicine
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Richard N. Kolesnick discloses the following relationships and financial interests:
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.